MK-3134

MK-3134 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-3134, covering 2015-11-06 to 2015-11-06. Get the full timeline:

Most recent: Clinical Trial Update: Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED) [Phase 1]

See pricing